Evaluation of antidiabetic activity of carnosol (phenolic diterpene in rosemary) in streptozotocin-induced diabetic rats.
This study was designed to investigate the hypolipidemic, anti-oxidant, and anti-diabetic activities of CS. In our experiment, the rats were divided into the following groups of 8 animals each: control, untreated diabetic, three CS (1, 5, 10 mg/kg/day)-treated diabetic groups. On the first day of the study, the diabetic groups were given streptozotocin (STZ) in a single intraperitoneal (i.p.) injection at a dose of 60 mg/kg for induction of diabetes. CS was injected (i.p.) to the treatment groups from 3 days after STZ administration during a period of 4 weeks. At the end of the experimental period, we assessed the serum le...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 31, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Connexin43 and myocardial ischemia-reperfusion injury.
Authors: Zu L, Wen N, Liu C, Zhao M, Zheng L Abstract The treatment and prevention of ischemic cardiomyopathy is one of the most concerned research points in cardiovascular field recently. Gap junction is the basic structure of cardiac electrophysiology, connexin is the basic unit of gap junctions, Connexin43(Cx43) is the most abundant member of Cx family in heart ,the normal expression of Cx43 is crucial for heart development,electrically coupled cardiomyocytes activities and the regulation of myocardial function. The connection between Cx43 and myocardial ischemia/reperfusion or reperfusion injury has become th...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 30, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Hypertensive Crisis: pharmacotherapy and complications.
Authors: Wani-Parekh P, Garcia-Blanco C, Mendez M, Mukherjee D Abstract Cardiovascular diseases (CVD) are the number one cause of death globally compared to any other cause. CVD accounts for approximately 17.3 million deaths per year and are rising. Hypertension is the leading risk factor for cardiovascular diseases. Approximately 80 million people suffer from hypertension in the U.S. While, majority of these individuals are on antihypertensive medications only 54% of individuals with hypertension are optimally controlled. Heart failure and stroke are some of the devastating complications of uncontrolled hypertensi...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 23, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Effects of an outpatient service rehabilitation programme in patients affected by pulmonary arterial hypertension: an observational study.
Authors: Bussotti M, Gremigni P, Pedretti RF, Kransinska P, Di Marco S, Corbo P, Marchese G, Totaro P, Sommaruga M Abstract BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterised by a severe impairment of functional status and quality of life (QoL). Use of rehabilitative programmes may help to improve outcomes. The aim of this pre/post test case series was to evaluate the impact of a training program, including sessions of aerobic and resistance exercise, inspiratory muscle reinforcement, slow breathing, relaxation, and psychological support, on functional outcomes. METHODS: Fifteen p...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 3, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Cardiovascular effect of Nigella sativa L. Aqueous Extract in Normal Rats.
Authors: Hebi M, Zeggwagh N, Benaji B, Michel JB, Eddouks M Abstract The present wok aims to evaluate the cardiovascular effect of Nigella sativa L. aqueous extract (NSAE) in normal rats. The in vivo experiment showed that the intravenous injection of NSAE at the doses of 50, 100 and 200 mg/kg of body weight produced a dose dependent reduction in the mean arterial blood pressure (MABP) (p
Source: Cardiovascular and Hematological Disorders Drug Targets - September 11, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Antidotal effects of curcumin against agents-induced cardiovascular toxicity.
This study found that curcumin may be effective in cardiovascular diseases induced by toxic agents including Streptozotocin, Doxorubicin, Cyclosporin A, Methotrexate, Isoproterenol, Cadmium, Diesel exhaust particle, Nicotine, Hydrogen peroxide, and tert-Butyl hydroperoxide. However, due to the lake of information on human, further studies are needed to determine the efficacy of curcumin as an antidote agent. The present study aimed to critically review the recent literature data from that regarding the protective effects of curcumin against agents-induced cardiovascular toxicity. PMID: 27492624 [PubMed - as supplied by...
Source: Cardiovascular and Hematological Disorders Drug Targets - August 8, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran.
Authors: Teleb M, Salire K, Wardi M, Alkhateeb H, Said S, Mukherjee D Abstract Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of atrial fibrillation is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagu...
Source: Cardiovascular and Hematological Disorders Drug Targets - August 3, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The effects of Zataria multiflora on blood glucose, lipid profile and oxidative stress parameters in adult mice during exposure to bisphenol A.
Authors: Samarghandian S, Azimini-Nezhad M, Farkhondeh T Abstract Background-The present study evaluated the effects of Zataria multiflora (Z. multiflora) ethanolic extract on the hyperglycemia induced by bisphenol A (BPA). Method-In the present research, the mice were randomly selected into the following categories of 6 mice in each group: group one, control (C); group two, which mice received 0.5 mg/kg of BPA, group three, which the mice received 2 mg/kg of BPA, group four, which exposed to 0.5 mg/kg of BPA and received Z. multiflora and group five, which exposed to 2 mg/kg of BPA and received Z. multiflora. The ...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 30, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Ischemic strokes in congenital bleeding disorders: comparison with myocardial infarction and other acute coronary syndromes.
CONCLUSIONS: The significance of these findings is discussed in view of the discrepancies observed between Ischemic stroke and Myocardial infarction. PMID: 27305946 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 18, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Antioxidants in the Practice of Medicine; What Should the Clinician Know?
Authors: Mukherjee D, Whayne TF Abstract Antioxidants offer protection against the damage potentially caused by free radicals, which usually involve an oxygen or nitrogen moiety, in living organisms. An antioxidant can be defined as a molecule that has the capability to inhibit the oxidation of another molecule, so, in other words, it is a reducing agent that is sufficiently stable to donate an electron to a circulating free radical and thereby result in its neutralization. Free radicals can be defined as any chemical species that has one or more mismatched electrons; these free radicals can cause a sequential reac...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 16, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The effect of Stevia on the chicken embryo heart.
CONCLUSION: It was suggested that stevioside didn't cause marked damages in heart tissues in chicken embryo model. PMID: 27229155 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - May 29, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Multiple drugs causing severe anemia in infective endocarditis.
MULTIPLE DRUGS CAUSING SEVERE ANEMIA IN INFECTIVE ENDOCARDITIS. Cardiovasc Hematol Disord Drug Targets. 2016 May 24; Authors: Singh A, Shetty PN, Singh BM, Devasia T Abstract Ceftriaxone and linezolid are commonly used antibiotics in infective endocarditis. Here we present a rare case of severe anemia caused by both the drugs via different mechanisms. Drugs have shown significant contribution in inducing anemia via hemolysis and bone marrow suppression in an infective endocarditis patient. PMID: 27215287 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - May 26, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Pharmacological interactions on blood pressure control in arterial hypertension, an issue not to be overlooked.
PHARMACOLOGICAL INTERACTIONS ON BLOOD PRESSURE CONTROL IN ARTERIAL HYPERTENSION, AN ISSUE NOT TO BE OVERLOOKED. Cardiovasc Hematol Disord Drug Targets. 2016 Jan 1; Authors: Ciulla MM, Benfenati C, Gallazzi E, Vivona P, Meazza R, Lombardi F Abstract Our vision of long-term treatment strategies for the prevention of target organ damage and eventually cardiovascular morbidity and mortality in essential arterial hypertension needs to be continually monitored and updated for at least three issues: 1 - the achievement of target pressure required to obtain the expected benefit requires continuous monitoring, ...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 18, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Authors: Rostagno C Abstract Despite widespread diffusion of pharmacological prophylaxis, deep venous thrombosis (DVT) is still a common cause of morbidity after major orthopedic surgery (total hip replacement -THR- and total knee replacement -TKR) . At present, clear evidence has been provided that pharmacological primary prophylaxis with low molecular weight heparin (LMWH) is associated with a significant decrease in the incidence of venous thromboembolism. The main limitation of LMWH prophylaxis however is the need for parenteral administration with a not negligible drop-out of treatment. Newer oral anticoagulan...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 18, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk assessment and Clinical Management.
Authors: La Farina F, Raparelli V, Napoleone L, Guadagni F, Basili S, Ferroni P Abstract In Italy, each year 500000 couples refer to specialized centers due to reproductive problems. Among them, recurrent pregnancy loss (RPL) represents a problem of great importance, given that it affects up to 5% of women of childbearing age. Infertility, on the other hand, is a condition that currently covers 10-20% of couples of reproductive age, being idiopathic in 20% of cases. Accumulating evidence support the concept that changes of blood coagulation, generically defined as the presence of a thrombophilic state (congenital o...
Source: Cardiovascular and Hematological Disorders Drug Targets - January 18, 2016 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

EDITORIAL: Novel Oral Anticoagulation-A Milestone in Anticoagulation History.
Authors: Yildiz M, Akin I PMID: 26666322 [PubMed - in process] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Rationale for Development of New Oral Anticoagulants.
Authors: Akin M, Widder J, Akin I, Brehm M, Schäfer A Abstract The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link's laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some ...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
Authors: Akin M, Schäfer A, Akin I, Widder J, Brehm M Abstract Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thrombembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade's classic anticoagulants like he...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The Use of Novel Oral Anticoagulants in Atrial Fibrillation.
Authors: Ansari U, Behnes M, Fastner C, Akin I Abstract Atrial fibrillation is known to be associated with an increased risk of ischaemic stroke and systemic embolism. After stratification using various risk calculation scores, patients were traditionally prescribed anticoagulants in the form of Aspirin or the traditional Vitamin K Antagonists. The use of Warfarin has proven to reduce incidents of ischaemic stroke; however its use has several limitations. The necessity for strict anticoagulation monitoring so as to maintain the narrow therapeutic range as measured by the international normalized ratio (INR) between...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

New Oral Anticoagulants in Coronary Artery Disease.
Authors: Behnes M, Fastner C, Ansari U, Akin I Abstract The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombi...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

New Oral Anticoagulation after Heart Valve Replacement.
Authors: El-Battrawy I, Baumann S, Huseynov A, Akin I Abstract Antithrombotic treatment after heart valve surgery is of utmost importance depending on the type of used valve. Since in the early 1960s, oral anticoagulation with vitamin K antagonist are the gold-standard for prevention of thromboembolism at replaced heart valves. The introduction of new oral anticoagulation has dramatically changed treatment strategy in patients with atrial fibrillation and in patients with venous thromboembolism like deep vein thrombosis and pulmonary embolism. However, to date, the use of these newer drugs is contraindicated after ...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Novel Oral Anticoagulation During Pulmonary Vein Isolation and Cardioversion.
Authors: Fastner C, Behnes M, Ansari U, Akin I Abstract Atrial fibrillation is an age-dependent disease with symptomatic and prognostic implications. Treatment options include rhythm as well as rate control. However, there is a need for anticoagulation depending on calculated individual annual risk. Treatment options include antiplatelet therapy, oral anticoagulation and the use of novel oral anticoagulation (NOACs). To date, the safety and efficacy of NOACs in atrial fibrillation is established in large mega-trials. However, there is still concern on the use of NOACs in invasive procedures such as coronary angiogr...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications.
Authors: Huseynov A, Baumann S, El-Battrawy I, Akin I Abstract The use of novel oral anticoagulation (NOACs) has emerged as an alternative for oral anticoagulation with vitamin-K antagonists in different clinical settings. However, despite the several advantages of these new drugs, there are also several limitations and cautious is recommended in different clinical settings in patients with a high comorbidity index. This review article will describe the current evidence of treatment monitoring, possible drug interaction, and will give an overview about treatment options in case of complications. PMID: 26666329...
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management.
In conclusion, the recent introduction of NOACs represents an opportunity for anticoagulative treatment regimes, while the benefits, risks and limitations should be reflected carefully. The purpose of this systematic review is to highlight features and to provide practical guidance of NOACs in comparison with VKAs that should be considered in a multifaceted decision making process to improve efficacy and safety. PMID: 26666330 [PubMed - in process] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - December 19, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

A Pilot Study to Assess Adenosine 5'-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection.
Authors: Yeung P, Tinkel J, Seeto D Abstract OBJECTIVE: To study the effect of exercise preconditioning on adenosine 5'triphosphate (ATP) metabolism in red blood cells and cardiovascular protection against injury induced by isoproterenol in vivo. METHODS: Male Sprague Dawley rats (SDR) were each exercised on a treadmill for 15 minutes at 10 m/min and 10% grade (n = 7) (LowEx), or 14 m/min and 22% grade (n = 8) (VigEx). Two hours after the exercise, each rat received a single dose of isoproterenol (30 mg/kg) by subcutaneous (sc) injection. Two separate groups of SDR were used as control: One received no exercise...
Source: Cardiovascular and Hematological Disorders Drug Targets - November 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates.
We examined data on 1,117 autopsy cases and found that the organ distribution of metastasis of cancers of the lung, pancreas, stomach, colon, rectum, uterine cervix, liver, bile duct, and esophagus involved the lung, liver, adrenal gland, bone/bone marrow, lymph node, and pleura/peritoneum. Cancers of the kidney, thyroid, ovary, choriocarcinoma, and breast, however, manifested different metastatic patterns. The distribution of leukemia and lymphoma metastases was quite different from that of epithelial cancers. On the basis of experimental studies, we believe that the anatomical-mechanical hypothesis should be replaced by ...
Source: Cardiovascular and Hematological Disorders Drug Targets - November 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Validity of oxygen-ozone therapy as integrated medication form in chronic inflammatory diseases.
VALIDITY OF OXYGEN-OZONE THERAPY AS INTEGRATED MEDICATION FORM IN CHRONIC INFLAMMATORY DISEASES. Cardiovasc Hematol Disord Drug Targets. 2015 Jul 1; Authors: Bocci V, Zanardi I, Valacchi G, Borrelli E, Travagli V Abstract The state-of-the-art of oxygen-ozone therapy is now clarified and all the mechanisms of action of medical ozone are within classical biochemistry and molecular biology. The outcomes of standard treatments in peripheral arterial occlusive disease (PAOD) and dry-form of age-related macular degeneration (AMD) have been compared with the documented therapeutic results achieved with ozonat...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 3, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Evaluation of a bone marrow dysmyelopoiesis immunophenotypic index for the diagnosis and prognosis of myelodysplastic syndromes.
EVALUATION OF A BONE MARROW DYSMYELOPOIESIS IMMUNOPHENOTYPIC INDEX FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES. Cardiovasc Hematol Disord Drug Targets. 2015 Jun 30; Authors: Verigou E, Lampropoulou P, Smyrni N, Kolliopoulou G, Sakellaropoulos G, Starakis I, Zikos P, Solomou E, Symeonidis A, Karakantza M Abstract BACKGROUND: Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders with significant heterogeneity in their clinical presentation and the prognosis of the patients. Several attempts have been made to incorporate flow cytometry (FC) findings into ...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 3, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Apixaban in venous thromboembolism in an Era of New Oral Anticoagulants.
Authors: Turagam MK, Velagapudi P, Adeola O, Chinnakotla B, Alpert MA Abstract Several new oral anticoagulants (NOAC) have been recently studied and approved for the prevention and treatment of venous thromboembolism (VTE) which includes deep vein thrombosis and pulmonary embolism. Although, NOACs possess several advantages when compared to traditional therapy each has its own limitations; especially in the elderly and in patients with low body weight, renal impairment and in those with high risk of bleeding. Apixaban is a factor Xa inhibitor recently approved for the treatment and prevention of VTE in the United S...
Source: Cardiovascular and Hematological Disorders Drug Targets - July 3, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Pathogenesis of neointima formation following vascular injury.
Authors: O' Brien ER, Ma X, Simard T, Pourdjabbar A, Hibbert B Abstract Revascularization remains the cornerstone of managing obstructive coronary artery disease. Although percutaneous coronary interventions involving the insertion of metal scaffolds, known as stents, has emerged as the preferred method of restoring vessel patency, as many as 30% of patients will experience a gradual re-narrowing of the lumen caused by neointima (NI) formation, resulting in a condition known as in-stent restenosis (ISR). ISR represents a significant limitation to percutaneous revascularization - however, abrogating NI formation fol...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Editorial [hot topic: ischemic stroke in very old patients (guest editor: Maria Cristina Zurru)].
Authors: Zurrú MC PMID: 21592059 [PubMed - indexed for MEDLINE] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention.
Authors: Chatterjee S, Chandra P, Guha G, Kalra V, Chakraborty A, Frankel R Abstract Aims: The absolute white blood cell (WBC) count and neutrophil to lymphocyte (N/L) ratio are predictors of death/myocardial infarction in patients who have undergone coronary angiography. We hypothesized that a pre-procedural elevated WBC count and an elevated N/L ratio would be a predictor of development of significant ventricular arrhythmias in subjects undergoing percutaneous coronary intervention (PCI). Methods and Results-We retrieved the data for all patients developing ventricular arrhythmia during PCI between 1999 to 2009 f...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Fibrosis, enzymatic and non-enzymatic cross-links in hypertensive heart disease.
Authors: Ciulla MM, Paliotti R, Carini M, Aldini G Abstract Myocardial fibrosis is commonly observed in left ventricular (LV) hypertrophied heart during Arterial Hypertension. This pathological change coupled with vascular stiffening with aging and diabetes may reduce the cardiovascular system elasticity contributing to the functional impairment. Both the LV adaptive response to the increasing blood pressure and the oxidative damage contribute to myocardial fibrosis; in particular, reactive oxygen species (ROS) induce the formation of reactive electrophilic carbonyl species by reacting with lipids and sugars which ...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

LPS in Patients with LV Dysfunction of Ischemic and Non-Ischemic Origin.
Conclusions: It is probable that LPS does not play any major role in the progression of LV dysfunction. The possible role of LPS in critical heart failure should therefore be better evaluated. PMID: 22044035 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Anti-platelet therapy for Acute Coronary Syndrome: A review of currently available agents and what the future holds.
Authors: Syed FA, Bett J, Walters DL Abstract Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidgrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischameic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent .Clopidgrel is a pro drug that required activation by hepatic metabolism and...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Pexelizumab, an Anti-C5 Complement Antibody for Primary Coronary Revascularization: A New Insight from Old Versions.
Authors: Lin GM Abstract Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to reduce reperfusion injury after coronary revascularization in acute myocardial infarction and severe coronary artery disease had been approved in animal studies and further demonstrated clinical benefits in phase II study: the COMMA trial and phase III study: the PRIMO-CABG trial. However, the negative results of pexelizumab were observed in the COMPLY trial and the APEX-AMI trial. In the APEX-AMI trial, the effectiveness of pexelizumab has reasoned to be prominent in high-risk patients. Similarly, an exploratory analysis...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Malignancy and Radiation-Induced Cardiotoxicity.
Authors: Mancuso L, Mancuso A, Scordato F, Pieri M, Valerio MC Abstract Mediastinal mass radiotherapy as adjuvant or primary treatment is usually performed for lung, breast and oesophagus cancer, for lymphoma and thymoma. However, untoward late cardiac and vascular adverse effects can develop that were underrecognized in the past because a very long latency from exposure to clinical manifestations is needed. Moreover, the true cumulative incidence of these complications is hard to correctly evaluate. Thoracic Radiotherapy (TR) may determine pathological involvement of pericardium, myocardium, cardiac valves, conduc...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Regulation of endothelial nitric oxide synthase in pathophysiological conditions.
Authors: Isenović E, Soskić S, Düngen HD, Dobutovic B, Elvis T, Simone I, Marche P Abstract The nitric oxide (NO) cascade and endothelial NO synthase (eNOS) are best known for their role in endothelium-mediated relaxation of vascular smooth muscle (VSM). NO generated by eNOS has been established as a key regulatory signaling molecule in the vasculature. The activities of eNOS are controlled by intracellular calcium/calmodulin (CaM) and by binding of the molecular chaperone heat-shock protein 90 (Hsp90). A number of studies have demonstrated a close association between insulin resistance (IR) and NO bioactivi...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Ox-LDL Particles: Modified components, Cellular uptake, Biological roles and Clinical assessments.
Authors: Najafi M, Roustazadeh A, Alipoor B Abstract Among concepts proposed to elucidate atherosclerosis process, the oxidative modification hypothesis is more considered to be investigated in studies. Based on the hypothesis, the LDL components are chemically modified due to oxidative stress within subendothelial space of vessels. The cells are able to recognize the oxidized LDL (ox-LDL) preparations so that inflammatory events spread through intracellular pathways and lead to the cellular dysfunction and the production of atherosclerotic plaques. The circulating ox-LDL level is suggested as biomarker of atheroge...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Importance of assessing the effect of statins on the function of high- density lipoproteins on coronary plaque.
In conclusion, the best coronary plaque regression index attributed to HDL-cholesterol elevation (PH index) was found in pitavastatin treatment, in comparison with the other 4 statins (atorvastatin, pravastatin, simvastatin, rosuvastatin) investigated in the articles scanned by their search. PMID: 22524170 [PubMed - indexed for MEDLINE] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Serum collagen markers and heart failure.
Authors: Lijnen PJ, Maharani T, Finahari N, Prihadi JS Abstract Increased myocardial collagen accumulation is present in almost every cardiac disease and plays an important role in the reduced heart function. N-terminal and C-terminal propeptides of collagen type I and III, the two major collagen types in the heart, can be assayed in serum.These propeptides (PINP, PIIINP, PICP, ICTP) reflect collagen synthesis and degradation. The use of these serum collagen biomarkers as prognostic or diagnostic tools is an area of active investigation. In this review article these studies will be discussed as well as the limitati...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Antithrombotic options for atrial fibrillation in 2012.
Authors: Rude J, Quevedo K, Rodriguez de Armas L, Mukherjee D Abstract Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therap...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Role of genetic factors in statins side-effects.
In conclusion, the picture of putative pharmacogenetic modulation of statins safety is reaching a growing body of evidence for translation into clinical practice but more specific studies for each single statin, in different clinical settings, both from genome-wide or competitive candidate genes evaluation, are needed before describing a definitive class-risk profile. PMID: 22524173 [PubMed - indexed for MEDLINE] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Ambulatory blood pressure monitoring in prehypertensive subjects.
Authors: Licitra R, Acconcia MC, Puddu PE, Pannarale G Abstract BACKGROUND: Although treatment of prehypertensives is feasible and effective, it is unclear how to define those who may benefit. We hypothesized that ambulatory blood pressure monitoring (ABPM) might be a tool for selecting prehypertensive subjects, classified according to the JNC 7, who later develop drug-treated hypertension. METHODS: Prehypertensives (n=107; 62 M, 45 F; age 50 ± 14 years) with or without cardiovascular risk factors were assessed for drug-treated hypertension development. They underwent ABPM at entry examination and were c...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Update on the important new drug target in cardiovascular medicine - the vascular glycocalyx.
Authors: Drake-Holland AJ, Noble MI Abstract We reviewed this subject in 2009, pointing out that, to the process of atherothrombosis, glycocalyx dysfunction and damage must be added to the previous known causitive factors. Glycocalyx dysfunction is possibly the very first step in the process of atherothrombosis, being a protective layer between the endothelial cells and the blood. We emphasise the unique feature of glycocalyx mediated vasodilatation in that it is initiated purely by mechanical changes, i.e., changes in vascular wall shear stress, allowing conduit arteries to adjust diameter to demanded blood flow r...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Innovative erythrocyte-based carriers for gene delivery in porcine vascular smooth muscle cells: basis for local therapy to prevent restenosis.
Authors: Lande C, Cecchettini A, Tedeschi L, Taranta M, Naldi I, Citti L, Trivella MG, Grimaldi S, Cinti C Abstract Vascular restenosis is affecting 30-40% of patients treated by percutaneous coronary angioplasty (PTCA). The advent of stenting reduced but not abolished restenosis. The introduction of drug eluting stent (DES) further reduced restenosis, but impaired endothelization exposed to intracoronary thrombosis as late adverse event. It is widely accepted that the endothelial denudation and coronary wall damages expose Vascular Smooth Muscle Cells (VSMC) to multiple growth factors and plasma circulating agents...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Effect of nicotine on ATPase, catalase and calcium levels in the presence of oligoelements in brain regions of young rats.
Authors: Guzman DC, Garcia EH, Delgadillo VN, Mejia GB, Olguin HJ, Perez JH, del Angel DS, Labra Ruiz NA Abstract UNLABELLED: The effect of nicotine on membrane alterations and fluidity changes in very young models remains unclear. The aim of this study was to evaluate the effect of nicotine on total ATPase, H(2)O(2) and calcium in brain of young rats in the presence of oligoelements. Male Wistar rats (weight 80 g) received intraperitoneally either a single dose or repeated doses for 4 days as follows: Group 1 (control) NaCl 0.9%; group 2 nicotine (1mg/kg); group 3 oligoelements (50 μl); and group 4 nicotine (1m...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Malignancy in common variable immune deficiency: report of two rare cases of gastrointestinal malignancy and a review of the literature.
In this study we review the occurrence of malignancy in patients with CVID and postulate mechanisms that may be involved indigent to this disease. We will also review the role of replacement immunoglobulin and discuss cancer screening in these high risk individuals. PMID: 22746346 [PubMed - indexed for MEDLINE] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients.
In conclusion, Cilnidipine is a useful agent to treat mild to moderate essential hypertension in China. PMID: 22746347 [PubMed - indexed for MEDLINE] (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research

Current and emerging therapies in primary myelofibrosis.
Authors: Ayyappan S, Janakiram M, Raghupathy R Abstract Primary myelofibrosis is a clonal hematopoietic disorder characterized by ineffective hematopoiesis and progressive bone marrow fibrosis. Patients with high risk myelofibrosis as determined by their advanced age, degree of anemia, leukocytosis, constitutional symptoms and high percentage of circulating blasts have a very short median survival of 2 years. In addition quality of life is significantly compromised due to cytokine induced constitutional symptoms, frequent transfusion for cytopenias and bulky splenomegaly. Progression to myelogenous leukemia occurs ...
Source: Cardiovascular and Hematological Disorders Drug Targets - June 4, 2015 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research